title: Changes in adiponectin multimer distribution in response to  atorvastatin treatment in patients with type 2 diabetes.
abstract: OBJECTIVE
  Multimeric high molecular weight (HMW) forms of adiponectin were previously shown to be inversely associated with the extent of atherosclerosis in males and are down-regulated in patients with the metabolic syndrome and type 2 diabetes. In this study, potential influences of atorvastatin therapy on adiponectin multimer distribution were studied in patients with type 2 diabetes.
  
  
  METHODS
  The effect of 40 mg atorvastatin on HMW, medium molecular weight (MMW), and low molecular weight (LMW) isoforms of adiponectin were investigated in 75 patients (23 females; 52 males) with type 2 diabetes in an 8-week-long, placebo-controlled and randomized study. Adiponectin multimeric isoforms were detected by Western blot analysis.
  
  
  RESULTS
  After atorvastatin therapy the median serum concentration of HMW adiponectin increased significantly by 42.3% (1.68 vs. 2.39 microg/ml; P < 0.001), while concentrations of MMW adiponectin and LMW adiponectin significantly decreased by 20.8% and 23.2%, respectively (MMW: 3.31 vs. 2.62 microg/ml, P = 0.047; LMW: 0.56 vs. 0.43 microg/ml, P = 0.033). Median total adiponectin levels were not significantly altered by atorvastatin treatment (6.0 vs. 6.2 microg/ml, P = 0.898). Consequently, the HMW: total-adiponectin ratio significantly increased by 25.0% (0.40 vs. 0.50; P = 0.013).
  
  
  CONCLUSIONS
  Atorvastatin therapy is associated with significant changes in adiponectin multimer distribution in patients with type 2 diabetes. Since total adiponectin levels were not affected by intervention, atorvastatin may shift adiponectin size towards the HMW form.
authors.affiliation: Department of Nephrology, Technische Universitaet Muenchen, Munich, Germany. maximilian.eynatten@lrz.tum.de
authors.forename: M
authors.initials: M
authors.lastname: von Eynatten
authors.forename: D
authors.initials: D
authors.lastname: Liu
authors.forename: A
authors.initials: A
authors.lastname: Bluemm
authors.forename: T
authors.initials: T
authors.lastname: Schuster
authors.forename: M
authors.initials: M
authors.lastname: Baumann
authors.forename: J
authors.initials: J
authors.lastname: Lutz
authors.forename: U
authors.initials: U
authors.lastname: Heemann
authors.forename: K A
authors.initials: KA
authors.lastname: Dugi
authors.forename: P P
authors.initials: PP
authors.lastname: Nawroth
authors.forename: A
authors.initials: A
authors.lastname: Bierhaus
authors.forename: P M
authors.initials: PM
authors.lastname: Humpert
mesh_terms: D052242:Adiponectin / Q000097:blood / Q000737:chemistry*; D000328:Adult; D000069059:Atorvastatin; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055503:Protein Multimerization; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin